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Abstract
Background:  The E-cadherin gene (CDH1) maps, at chromosome 16q22.1, a region often
associated with loss of heterozygosity (LOH) in human breast cancer. LOH at this site is thought
to lead to loss of function of this tumor suppressor gene and was correlated with decreased
disease-free survival, poor prognosis, and metastasis. Differential CpG island methylation in the
promoter region of the CDH1 gene might be an alternative way for the loss of expression and
function of E-cadherin, leading to loss of tissue integrity, an essential step in tumor progression.
Methods: The aim of our study was to assess, by Methylation-Specific Polymerase Chain Reaction
(MSP), the methylation pattern of the CDH1 gene and its possible correlation with the expression
of E-cadherin and other standard immunohistochemical parameters (Her-2, ER, PgR, p53, and K-
67) in a series of 79 primary breast cancers (71 infiltrating ductal, 5 infiltrating lobular, 1 metaplastic,
1 apocrine, and 1 papillary carcinoma).
Results: CDH1 hypermethylation was observed in 72% of the cases including 52/71 ductal, 4/5
lobular carcinomas and 1 apocrine carcinoma. Reduced levels of E-cadherin protein were observed
in 85% of our samples. Although not statistically significant, the levels of E-cadherin expression
tended to diminish with the CDH1  promoter region methylation. In the group of 71 ductal
cancinomas, most of the cases of showing CDH1 hypermethylation also presented reduced levels
of expression of ER and PgR proteins, and a possible association was observed between CDH1
methylation and ER expression (p = 0.0301, Fisher's exact test). However, this finding was not
considered significant after Bonferroni correction of p-value.
Conclusion: Our preliminary findings suggested that abnormal CDH1 methylation occurs in high
frequencies in infiltrating breast cancers associated with a decrease in E-cadherin expression in a
subgroup of cases characterized by loss of expression of other important genes to the mammary
carcinogenesis process, probably due to the disruption of the mechanism of maintenance of DNA
methylation in tumoral cells.
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Background
Breast cancer is the second leading cause of cancer-related
morbidity and mortality in women worldwide. In 2005,
more than 49,500 new cases of breast cancer among Bra-
zilian women are expected. Despite the recent trend in
decreasing in mortality rates, probably due to improve-
ments in early detection, approximately 50% of cases were
diagnosed as advanced disease (grade III and IV tumors)
in recent years in our country [1].
The natural history of breast cancer is characterized by het-
erogeneity within and between patients, since tumors
with similar histopathological diagnosis can follow differ-
ent clinical courses and show different responses to ther-
apy [2]. These cancers are generally considered to result
from the accumulation of multiple clonal changes in
genes that regulate cell growth and differentiation [3,4].
One of the mechanisms involved in the carcinogenesis
process is loss of tumor suppressor gene function, which
normally acts as a negative regulator of cell proliferation.
Tumor suppressor gene inactivation contributes to car-
cinogenesis by conferring certain advantages to growth
that lead to tumor progression. It is generally thought that
these genes are recessive, requiring mutation or loss of
both alleles for functional inactivation. The loss of heter-
ozygosity (LOH) in sporadic cancers reflects somatic dele-
tions that involve specific chromosomal regions
associated with a tumor suppressor gene located within
the deleted region [5].
Among the genome regions that undergo LOH in breast
cancer is the long arm of chromosome 16 [6-8]. Using
radiation hybrid mapping and microsatellite markers,
Chalners et al [9] showed a high rate of LOH involving the
cluster of cadherin genes at 16q21-q22.1, with the CDH1
gene being the most frequent lost marker in breast cancer.
The CDH1 (16q22.1) gene encodes the transmembrane
glycoprotein E-cadherin that is important in maintaining
homophilic cell-cell adhesion in epithelial tissues [10].
The cadherins are a family of Ca2+ dependent adhesion
molecules that function in cell recognition and tissue
morphogenesis. Alterations in E-cadherin expression have
been related in several cancer types and correlated with
pathological features such as poor tumoral differentia-
tion, infiltrative growth, lymph node metastasis and
decreased patient survival [11-13].
Compelling experimental evidence indicates that the
CDH1 gene is a tumor suppressor. Germ line mutations in
this gene predispose affected individuals to diffuse-type
gastric cancer and it was also detected in one family with
a history of diffuse gastric cancer and early-onset breast
cancer [14]. Further evidence has been offered by the
identification of somatic inactivating mutations. In spo-
radic infiltrating lobular carcinomas (ILCs), most muta-
tions found in the CDH1 gene were out-of-frame, which
were predicted to yield secreted truncated E-cadherin frag-
ments. In most cases these mutations occurred in combi-
nation with loss of the wild type allele [15-17]. The
complete absence of E-cadherin expression, due to the
presence of classical inactivating mutations and deletions,
is a feature of ILCs [18].
While immunohistochemical studies have demonstrated
that reduced or absent E-cadherin expression is also com-
mon in infiltrating ductal carcinomas (IDCs) [18,19], in
the majority of these cases, CDH1 mutations were rare or
absent. Recently, it was demonstrated that epigenetic
silencing of the gene CDH1 by CpG island methylation of
its promoter region, occurs in some human breast cancer
cell lines, as well as in unselected primary breast cancer
[20,21]. Nass et al [22] demonstrated that hypermethyla-
tion of the CDH1 promoter region was evident in 30% of
in situ ductal carcinomas and increased to 60% in IDCs. In
this study, we reported aberrant methylation of the 5'CpG
island of the CDH1 gene associated with reduced levels of
E-cadherin expression in breast cancer.
Methods
Patients
Seventy nine breast carcinoma samples (71 IDCs, 5 ILCs,
1 apocrine, 1 metaplastic, and 1 papillary) were obtained
from seventy nine patients at Amaral Carvalho Hospital,
Jaú, São Paulo, Brazil from 2000 to 2004. The patients
were accrued consecutively and the inclusion criteria were
no previous new histologic diagnosis of breast cancer. The
patients had undergone segmental resection or mastec-
tomy and none of the patients had received radiotherapy
or chemotherapy before surgery. All the patients were
advised of the procedures and provided written informed
consent. This study was approved by the Brazilian Ethics
Committee (CONEP 694/1999). Patients were regularly
followed postoperatively. Immediately after surgery, the
tumor samples were frozen at -80°C. Each sample was
histopathologically evaluated to ensure the presence of at
least 80% of tumoral cells. The medical records of all
patients were examined to obtain clinical and histopatho-
logical information. The family history of cancer consid-
ered first-degree and second-degree relatives with cancer
as informative, and whenever possible, the evidence of
cancer was based on documented medical records or
ascertained from the death certificate. The histopatholog-
ical diagnoses of the tumors were described according to
the WHO International Classification of Disease for
Oncology [23]. The clinical staging was determined by the
TNM Staging System [24]. The malignancy of infiltrating
carcinomas was scored according to the Scarff-Bloom-
Richardson classification [25].BMC Cancer 2006, 6:48 http://www.biomedcentral.com/1471-2407/6/48
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Immunohistochemical analysis
Standard immunohistochemical detection, with minor
modifications, was performed on sections from archival
paraffin embedded tissue. Protein expression was studied
using specific antibodies against the estrogen receptor
(ER) (clone RTU-ER-6F11, Novocastra, Newcastle, UK,
1:50 dilution), the progesterone receptor (PgR) (mono-
clonal mouse anti-human progesterone receptor 1A6,
Dako, Carpinteria, CA, USA, 1:50 dilution), p53 (mono-
clonal mouse anti-human p53 protein clone DO-7, Dako,
dilution 1:200), Ki-67 (monoclonal mouse anti-human
ki-67 antigen clone MIB-1, Dako, dilution 1:100), Her-2
(policlonal rabbit anti-human cerbB-2 oncoprotein,
Dako, dilution 1:800) and E-cadherin (monoclonal
mouse anti human E-cadherin NCH-384, Dako, dilution
1:25). Positive and negative controls for each marker were
routinely performed during experiments. Slides were dis-
tributed randomly to two independent blinded observers
(FCQ and FAMN). If any discrepancies between classifica-
tions of samples arose, they were reviewed and the final
results reached by consensus. In areas of well-preserved
tissue, the fraction of the infiltrating part of the neoplasm
was scored. Tumors were classified by intensity of staining
and the percentage of cells showing antibody reactivity.
The ER, PgR, and p53 sections were scored for the immu-
nohistochemical signal as follows: weak (1+), moderate
(2+), and strong (3+) staining in >10% of the tumor cells
or absent (0). The Ki-67 sections were scored for the per-
centage of cells stained. For E-cadherin and Her-2, the
strength of the membranous staining was recorded by a
four-step scale 0, 1+ to 3+ as follows: continuous staining
of membrane (3+), continuous staining present in >10%
of the tumor cells (2+), focal or discontinuous staining
present in >10% of tumor cells (1+), and staining in <10%
of infiltrating cells (0). Further, for E-cadherin expression
we evaluated the staining in the cell membrane and in the
cytoplasm.
DNA extraction
Genomic DNA was prepared from frozen tumor tissues by
standard SDS/proteinase K digestion followed by phenol
and chloroform extraction and ethanol precipitation.
Treatment with sodium bisulfite
The conversion of DNA by sodium bisulfite was per-
formed using an established protocol [26], with modifica-
tions. Initially, 1–2 μg of genomic DNA were denatured
with 2 M NaOH at 50°C for 20 min (final concentration
of 0.2 M NaOH), followed by incubation with freshly pre-
pared 2.5 M sodium bisulfite/1 M hydroquinone, pH 5.0,
in a total volume of 520 μl, at 70°C for 3 h. The DNA was
purified with the Wizard DNA Clean-UP System
(Promega. Madison, WI, USA). The modification of the
DNA was completed by the addition of 5.0 μl of NaOH 3
M at room temperature during 10 min. The precipitation
was carried out through the addition of 75 μl of ammo-
nium acetate 5 M (pH 7,0), 350 μl of ethanol and 1.0 μl
of glycogen (20 μg/μl) (Invitrogen, Life Technologies,
Carlsbad, CA, USA). The bisulfite-modified DNA was
resuspended in 30 μl of sterile water, and stored at -20°C.
Methylation-Specific Polymerase Chain Reaction (MSP)
The methylation pattern within the CpG island in exon 1
of the CDH1 gene (sequence -126 bp to +144 bp relative
to transcription start, GenBank accession number
D49685) was determined using a nested-PCR approach
that has been published previously [27]. In the first round
of PCR, bisulfite-treated DNA was amplified using the
primers 5'-GTTTAGTTTTGGGGAGGGGTT-3, (sense) and
5'-ACTACTACTCCAAAAACCCATAACTAA-3' (antisense).
The cycling conditions consisted of an initial denaturation
step at 95°C for 5 min, followed by 35 cycles of 95°C for
1 min, 50°C for 30 sec, 72°C for 1 min. The size of the
product after this initial PCR reaction was 270 bp. For the
second PCR, 5 μl of this product was used for MSP. The
nested primers for the methylated sequence reaction were
5'-TGTAGTTACGTATTTATTTTTAGTGGCGTC-3' (sense)
and 5'-CGAATACGTCGAATCGAACCG-3' (antisense),
and primers sequences for the unmethylated sequence
were 5'-TGGTTGTAGTTATGTATTTATTTTTAGTGGTGTT-
3' (sense) and 5'-ACACCAATACAACAAATCAAACCAAA-
3' (antisense). The reactions were performed in a total vol-
ume of 25 μl containing 0.25 μM of each primer pair, 200
μM of each dNTP, 20 mM Tris-HCl, pH 8.4, 50 mM KCl,
1.5 mM MgCl2, and 1 U of Taq polymerase. The PCR
parameters were the same listed above, except that the
annealing temperature used for both primer pairs was
53°C. The product sizes of the methylated and unmethyl-
ated amplicons were 112 bp and 120 bp, respectively. The
amplified products were visualized after electrophoresis
in 6% polyacrylamide gel and silver nitrate staining [28].
Water blanks were included in each assay.
DNA from lymphocytes of healthy volunteers treated with
SssI  methyltransferase (New England Biolabs, Beverly,
MA, USA) and then subjected to bisulfite modification
was used as positive controls for methylated alleles. The
reaction was performed in a total volume of 50 μl contain-
ing 10 μg of genomic DNA, 10 U of SssI methylase, 160
mM of S-adenosyl-metionina, 50 mM of NaCl, 10 mM of
Tris-HCl, 10 mM of MgCl2, 1 mM of DTT pH 7.9, during
18 hours at 37°C.
Statistical analysis
Descriptive statistics, such as mean, SD, and percentage
were used to summarize a patient's data and gene hyper-
methylation status. Due to the large number of compari-
sons in the same sample group, pairwise associations
between CDH1 methylation patterns and immunohisto-
logical markers, demographic and clinical variables wereBMC Cancer 2006, 6:48 http://www.biomedcentral.com/1471-2407/6/48
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assessed via Fisher's exact test with a 5% level of signifi-
cance. These pairwise tests utilized the following dichoto-
mous variables, which were defined prior to any analysis
on the basis of the staining index defined as absent/
reduced expression levels (scores 0, 1, and 2) and posi-
tive/maximum staining (score 3) for E-cadherin, Her-2,
ER, PgR, proteins. To p53 protein, the expression level was
categorized as negative (scores 0 and 1) or positive (scores
2 and 3). The statistical tests were performed using the sta-
tistical software package SAS/STAT, version 6.0 (SAS Insti-
tute, Inc., Cary, NC, USA). The Bonferroni correction for
the multiple comparisons was applied to adjust the p-
value.
Results
The mean age at diagnosis of the primary breast cancer
was 59.6 ± 19.8 years, ranging from 30 to 94 years. The
nested PCR approach was used to detect the CDH1 gene
methylation pattern, after the treatment of tumoral
genomic DNA with sodium bisulfite. In all samples, we
detected the amplicon of 120 bp from unmethylated alle-
les. The amplification product of 112 bp from methylated
alleles was observed in 52 out of 71 IDCs (73.2%), in four
out of five ILCs, and in the apocrine carcinoma. The
hypermethylation of the promoter of the gene CDH1 was
detected in 11 out of 17 cases that reported positive famil-
ial history of cancer. Representative examples of MSP of
the CDH1 gene are illustrated in Figure 1.
I) Representative examples of MSP for CDH1 gene in infiltrating ductal carcinomas Figure 1
I) Representative examples of MSP for CDH1 gene in infiltrating ductal carcinomas. Lanes (m) and (u) correspond to reactions 
specific for methylated and unmethylated DNA, respectively. M, molecular weight DNA marker. II) Patterns of E-cadherin 
expression in ductal breast carcinomas stratified according a four-step scale: a. negative; b. 1+; c. 2+; and d. 3+. The sections 
were counterstained with hematoxylin. 400× magnification.BMC Cancer 2006, 6:48 http://www.biomedcentral.com/1471-2407/6/48
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Due to the large number of comparisons in the same sam-
ple group, we applied the Bonferroni correction. This type
of adjustment recommended a significance level of 0.005
to each of the ten tests performed. Table 1 shows the
details of pairwise associations between CDH1  gene
methylation and clinical and histological parameters in
the group of 71 IDCs. No statistically significant differ-
ences in the frequencies of CDH1 gene promoter methyl-
ation were found between the patients at ages ≤ 50 and >
50 years old; lymph nodes status (more or less than 4 pos-
itive lymph nodes); clinical stages, histological grade and
immunohistochemical analysis.
In the group of IDCs, CDH1 promoter methylation was
found in 1 tumor showing absence of E-cadherin expres-
sion and in 45 weakly positive tumors (scores 1+ and 2+).
Discrepant data was observed in six IDCs that showed
intense staining for E-cadherin expression (score 3+) and
concomitant CDH1 methylation. All these six cases also
presented inflammatory cells, with intense (2 cases),
moderate (2 cases), and discrete (2 cases) leukocytes infil-
tration. Of the unmethylated cases, five were E-cadherin
positive and 14 showed reduced levels of expression (Fig-
ures 1 and 2).
We also compared the methylation pattern of the CDH1
gene and its possible correlation with the expression of E-
cadherin and other standard immunohistochemical
parameters (Her-2, ER, PgR, p53, and Ki-67) in this sub-
group of patients with 71 IDCs. Most of the cases with
reduced ER expression (scores 0 to 2+) presented hyper-
methylation (37 out of 45 cases); furthermore, 11 out of
26 cases with ER expression 3+ showed unmethylated
CDH1 (p = 0.0301, Fisher's exact test). Similarly, a high
frequency of cases showing reduced levels of PgR (scores
0 to 2+) protein also presented CDH1 hypermethylation
(37 out of 48 cases). Of the cases showing strong PgR
staining, 15 were methylated and 8 were unmethylated.
On average, the patients were accompanied by a follow-
up of 32 months (ranging from 12 to 59 months). During
these intervals three patients died from unrelated causes.
Of the methylated cases, two IDCs evolved to bone and
lung metastasis after a post-surgery period of 38 and 5
months, respectively. Two other cases presented local
recidive after 4 and 22 months. In the group of 19 cases
negative for CDH1 hypermethylation, we detected two
cases that presented bone and lung metastasis.
The immunohistochemical analysis showed intense E-
cadherin staining in the metaplastic carcinoma, weak
staining in both the papillary and apocrine carcinoma. All
ILCs were negative for the expression of E-cadherin.
Discussion
Reduced expression of E-cadherin is regarded as one of the
main molecular events involved in the dysfunction of the
cell-cell adhesion system, triggering cancer invasion and
metastasis [29]. In our study, we correlated the hyper-
methylation at the CDH1 locus and the E-cadherin expres-
sion levels determined by immunohistological analysis in
79 unselected primary breast tumors. Based on a nested
PCR approach, we detected CDH1 hypermethylation in
52/71 IDCs, 4/5 ILCs and in the apocrine carcinoma.
Nested MSP is a two-step PCR that has the sensitivity to
Frequency distribution of the CDH1 methylation pattern in  71 infiltrating ductal carcinomas, categorized by the protein  expression levels of A) E-cadherin, B) ER and, C) PgR,  respectively Figure 2
Frequency distribution of the CDH1 methylation pattern in 
71 infiltrating ductal carcinomas, categorized by the protein 
expression levels of A) E-cadherin, B) ER and, C) PgR, 
respectively.BMC Cancer 2006, 6:48 http://www.biomedcentral.com/1471-2407/6/48
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detect methylated DNA molecules when they comprise as
little as 5% of the total complex DNA sample [30] or 1
methylated allele in the presence of 1000–2000 unmeth-
ylated alleles [31].
Aberrant methylation of the promoter region is consid-
ered one of the major mechanisms for the silencing of
cancer-related genes, resulting in down-regulation of gene
expression. It has been demonstrated that CpG island
hypermethylation is implicated in the loss of expression
of a variety of critical tumor suppressor and growth regu-
latory genes distributed in several categories including cell
cycle regulating, steroid receptors, tumor susceptibility,
carcinogen detoxification, cell adhesion and inhibitors of
matrix metalloproteinases [20,21]. In breast cancer,
CDH1 promoter methylation has been reported in ~30%
of in situ ductal carcinomas and increased substantially to
nearly 60% in metastatic tumors [22]. Furthermore, this
gene is one of the most frequently inactivated by methyl-
ation in sporadic breast cancer [32], as well in DNA sam-
ples obtained from plasma of invasive breast cancer
patients [33], from fine needle washings from breast
lesions [34], and in sentinel lymph node metastasis [35].
These findings suggested that CDH1 promoter methyla-
tion is an important event associated with the pathogene-
sis of breast cancer.
Table 1: CDH1 promoter methylation distribution according to clinical variables and immunohistochemical analysis in 71 IDCs.
Variable CDH1 methylation p value*
Presence N (%) Absence N (%)
Age 0,7842
≤50 19 (76%) 6 (24%)
>50 33 (72%) 13 (28%)
Lymph nodea 0,5049
≤4 42 (75%) 14 (25%)
>4 09 (64%) 5 (36%)
Clinical Stage 0,5268
I 9 (90%) 1 (10%)
IIA 16 (67%) 8 (33%)
IIB 17 (68%) 8 (32%)
IIIA 4 (100%) 0
IIIB 6(75%) 2 (25%)
Histologic grade 0,4282
I 2 (50%) 2 (50%)
II 37 (76%) 12 (24%)
III 13 (72%) 5 (28%)
Immunohistochemical
E-cadherin 0,1496
negative/reduced expression 
(0,1+,2+)
46 (77%) 14 (33%)
positive (3+) 6 (55%) 5 (45%)
Her-2 0,4339
negative (0,1+,2+) 47 (75%) 16 (25%)
positive (3+) 5 (63%) 3 (37%)
p53 1,0000
negative (0,1+) 42 (72%) 16 (28%)
positive (2+,3+) 10 (77%) 3 (23%)
ER 0,0301
negative/reduced expression 
(0,1+,2+)
37 (82%) 8 (18%)
positive (3+) 15 (58%) 11(42%)
PgR 0,3910
negative/reduced expression 
(0,1+,2+)
37 (77%) 11 (23%)
positive (3+) 15 (65%) 8 (35%)
Ki-67 0,0565
≤25% 27 (64%) 15 (36%)
>25% 25 (86%) 4 (14%)
* – p-value obtained from Fisher's exact test. Bonferroni correction was applied to statistical adjustment of each p-value (statistically significant p < 
0,005); a 70 patients contributed data.BMC Cancer 2006, 6:48 http://www.biomedcentral.com/1471-2407/6/48
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In the present study, the methylation pattern of the CDH1
gene was not correlated with the age of patients at diagno-
sis suggesting that they are not due to age-related methyl-
ation changes [36] but probably is correlated with the
deregulation of the methyltransferase activity during
tumor progression [37]. Disruption of the maintenance
mechanism of methylation could lead to a genomic wide
effect with several CpG islands showing abnormal meth-
ylation patterns; however, this event is considered non-
random in tumor cells, as suggested by abnormal tumor-
specific methylation profiles [32]. Nass et al. [22] reported
previously that coincident methylation in both CpG
islands of CDH1 and the estrogen receptor gene increases
with advancing disease, suggesting that malignant pro-
gression of ductal carcinomas involves the accumulation
of multiple epigenetic hits. This association was con-
firmed by Perrela et al. [32] which identified other meth-
ylated genes associated with estrogen receptor promoter
hypermethylation.
We observed a high frequency of cases with CDH1 pro-
moter hypermethylation and reduced expression of the
estrogen receptor: 45 IDCs showed a decrease in ER levels
(scores 0 – 2+), and 37 of them presented CDH1 hyper-
methylation. The progesterone receptor is another gene
that is also inactivated by hypermethylation [38]. CDH1
hypermethylation was observed in 37 out of 48 cases that
showed reduced expression of PgR protein (77%). In con-
trast, in the group showing strong PgR staining, 15 out of
23 cases presented CDH1  hypermethylation. Addition-
ally, we detected the complete absence of ER and/or PgR
expression in 19 out of 52 (37%) IDCs samples showing
methylation of the CDH1 gene. These data support the
hypothesis that disruption of the maintenance mecha-
nisms of the methylation pattern could result in distinct
hypermethylation profiles of primary breast cancer, with
tumor subsets characterized by reduced expression of spe-
cific cancer-related genes. In IDCs, expression studies have
routinely revealed that loss of expression of E-cadherin
and ER exhibits heterogeneity. Similar to our findings,
early studies have demonstrated that the heterogeneous
patterns of CpG island methylation parallel the heteroge-
neous loss of both ER and E-cadherin expression in these
tumors [39,40]. Thus, it seems likely that the accumula-
tion of epigenetic changes may contribute to the dimin-
ished expression of key genes for the mammary
carcinogenesis process.
Seventeen patients reported positive familial history of
cancer; six of them presented breast cancer history
between first and/or second-degree relatives. The hyper-
methylation of the promoter of the gene CDH1  was
detected in 11 out of these 17 cases, including all six cases
with familial breast cancer history. Reduced levels of E-
cadherin protein were observed in four out of six cases.
Most of these cases showed decreased levels of ER and PgR
protein: two cases were negative for both and reduced
expression of at least one protein was detected in four
tumors. Although distinct differences were observed in
hypermethylation profiles in cancers occurring in the
familial setting, Esteller et al. [41] reported that in BRCA1
tumors  CDH1  methylation frequencies resembled spo-
radic breast cancer.
Several reports have demonstrated the association either
of the CDH1 gene methylation [22,32-35] or the abnor-
mal expression of E-cadherin in breast cancer progression
[40]. However, there are a limited number of studies
directly correlating CDH1  methylation and E-cadherin
expression in the same sample of breast carcinomas [42].
In our study, CDH1 promoter methylation was not uni-
formly associated with the loss of E-cadherin expression.
Overall, reduced expression of E-cadherin (moderate,
weak or absence of staining in cell membranes) was
observed in 85% of our samples. Although not statisti-
cally significant, the intensity of E-cadherin staining
tended to diminish with methylation of the CDH1 pro-
moter region: 65% of the IDCs (46 out of 71 cases)
showed concomitant reduced levels of E-cadherin and
CDH1 hypermethylation. In 14 IDCs (20%), we detected
only unmethylated CDH1 alleles despite reduced staining
for E-cadherin. Several studies have demonstrated that E-
cadherin expression may be repressed by mechanisms
other than promoter hypermethylation, such as allele loss
(LOH), gene mutation, changes in chromatin structure
[43], and alterations of specific transcription pathways
regulating the expression of the CDH1  gene [44,45].
Besides, of the methylated tumors, 6 cases showed strong
E-cadherin staining (score 3+). CpG island hypermethyla-
tion constitutes a positively detectable signal with a very
high sensitivity [46], thus intratumoral heterogeneity and
the sensitivity of the nested MSP approach could explain
these discrepant results. Alternatively, it has been demon-
strated that infiltrating leukocytes can originate a methyl-
ation specific PCR fragment, making the detection and
interpretation of tumor-associated altered methylation
patterns more difficult [47]. Our results support this
hypothesis because intense (2 cases), moderate (2 cases),
and discrete (2 cases) leukocytes infiltration was detected
in these six cases.
In our study, we did not find an association between
CDH1 methylation and the Her-2 and p53 status. Her-2
over-expression was detected in 8 IDCs, of which 5
showed  CDH1  hypermethylation. Although an inverse
correlation has been related between the E-cadherin levels
and Her-2 over-expression [48], some studies have
detected that E-cadherin expression persisted into later
stages of the disease, and was associated with Her-2
expression [49,50]. One explanation for this discrepancyBMC Cancer 2006, 6:48 http://www.biomedcentral.com/1471-2407/6/48
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is that gene expression is diverse and the studies are con-
ducted on a large range of patients with ethnic and socio-
economic variables. In our country, most breast cancer
patients are diagnosed in advanced stages. Thirty-seven
out of 79 cases showed clinical and or histological param-
eters of worse prognostic, including histologic grade II –
III, positive lymph nodes, tumor size, and high Ki-67 (>
25%). However, all patients presented a favorable out-
come after more than 24 months of follow-up (25–59
months), none of them recidivated or developed metasta-
sis. In this particular subset of high risk of breast cancer,
31 tumors showed low E-cadherin levels and CDH1
hypermethylation was detected in 21 of them (68%). His-
topathological analysis has revealed inconsistencies in the
correlation of E-cadherin expression and prognosis in
breast cancer. Our data are in agreement with Howard et
al. [45], who find no correlations between E-cadherin
expression and overall survival in breast cancer patients.
Different mechanisms are involved in the altered E-cad-
herin expression seen in different subtypes of breast carci-
nomas. In ILCs, the complete loss of E-cadherin
expression has been consistent with biallelic inactivation
of CDH1 by promoter methylation, mutation or allelic
loss in any combination [40,51]. In our study, we detected
absence of E-cadherin expression in all five cases of ILCs
and in four of them there was concomitant CDH1 pro-
moter hypermethylation, suggesting that epigenetic
changes of CDH1 gene occurs in breast cancer, irrespective
of the histological type.
Conclusion
In conclusion, abnormal CDH1  methylation occurs in
high frequencies in infiltrating breast cancers. Although
considered not statistically significant, in a subgroup of
cases, this finding was associated with the low expression
levels of others genes (ER and PGR) probably due to the
disruption of the maintenance mechanism of DNA meth-
ylation in tumoral cells. Our preliminary findings needed
to be confirmed by new studies. The correlation between
CDH1 hypermethylation and the reduced expression of
the estrogen receptor is indirect evidence connecting
estrogen receptor function, transcriptional repression,
and E-cadherin expression in breast cancer. The dynamic
nature of epigenetic regulation including changes in DNA
methylation patterns, in expression and/or function of
trans/acting factors and chromatin mediated effects, could
explain the lack of uniformity in the CDH1 hypermethyl-
ation and the loss of E-cadherin expression observed at
the immunohistochemical level.
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